4 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 4 separate news trends connected to Obesity Drug, spanning June 23, 2026 through August 24, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 36 article observations and 34 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
Amgen's decision to drop an obesity drug in phase 1 trials has intensified competition in the pharmaceutical sector.
Eli Lilly is expanding access to its experimental obesity drug, Retatrutide, ahead of approval.
Speculation swirls around a 79-year-old patient who received an experimental weight loss drug, with former President Trump as the suspected recipient.